Long Shortz with Neurotech: Inside the groundbreaking science of NTI164

Neurotech continues to develop its innovative NTI-164, a cannabis based drug used to treat children with neurological disorders.

Neurotech (ASX:NTI) chief medical advisor USA Dr. Bonni Goldstein joins host Tylah Tully to discuss the promising future of the company's NTI164, a cannabinoid-based therapy for children with neurological disorders like autism, Rett syndrome and PANS/ PANDAS.

Dr. Goldstein shares her journey from paediatric emergency medicine to becoming a leading advocate for evidence-based botanical treatments, highlighting the safety, efficacy, and potential of NTI164 to transform paediatric care.

Watch the video to learn more.

This video was developed in collaboration with Neurotech, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Neurotech: Inside the groundbreaking science of NTI164